RT Journal Article SR Electronic T1 Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.22.20137695 DO 10.1101/2020.06.22.20137695 A1 Hicks, Jennifer A1 Klumpp-Thomas, Carleen A1 Kalish, Heather A1 Shunmugavel, Anandakumar A1 Mehalko, Jennifer A1 Denson, John-Paul A1 Snead, Kelly A1 Drew, Matthew A1 Corbett, Kizzmekia A1 Graham, Barney A1 Hall, Matthew D A1 Memoli, Matthew J A1 Esposito, Dominic A1 Sadtler, Kaitlyn YR 2020 UL http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137695.abstract AB In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other Betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialArchival (pre2019) serum samples (n = 114) were collected between January 2014 and December 2018 from healthy adults (aged 18 to 55 years) through an existing NIH study NCT01386424. High-incidence community samples are deidentified uncoded samples donated from a community blood draw from donors in New York and New Jersey in April 2020.Funding StatementThis research was supported in part by the Intramural Research Program of the NIH, including the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Allergy and Infectious Disease, and the National Center for Advancing Translational Sciences. This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The negative controls were collected under an approved NIH protocol listed on ClinicalTrials.gov NCT01386424. All other samples used were uncoded, deidentified samples collected with local IRB approval and determined to be IRB exempt by the NIH IRB for us to receive and use for this analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request after formal publication of manuscript.